Efficacy and safety of minimal dose (

Published

Journal Article (Academic article)

Abciximab decreases adverse cardiac ischemic events, and in some subgroups, decreases the need for revascularization after percutaneous coronary intervention (PCI). However, abciximab may cause bleeding complications and thrombocytopenia after PCI. We hypothesized that the efficacy and safety of PCI would be maintained, if not improved, when performed using abciximab accompanied by only minimal doses (

Duke Authors

Cited Authors

  • Denardo, SJ; Davis, KE; Reid, PR; Tcheng, JE

Published Date

  • January 2003

Published In

Volume / Issue

  • 91 / 1

Start / End Page

  • 1 - 5

International Standard Serial Number (ISSN)

  • 0002-9149

Language

  • English